Edition:
United States

Veloxis Pharmaceuticals A/S (VELOX.CO)

VELOX.CO on Copenhagen Stock Exchange

1.05DKK
24 May 2017
Change (% chg)

kr.-0.01 (-0.94%)
Prev Close
kr.1.06
Open
kr.1.06
Day's High
kr.1.06
Day's Low
kr.1.04
Volume
402,321
Avg. Vol
1,036,038
52-wk High
kr.1.49
52-wk Low
kr.0.93

Latest Key Developments (Source: Significant Developments)

Veloxis Pharmaceuticals Q1 operating loss narrows to $5.2 mln
Wednesday, 17 May 2017 01:23am EDT 

May 17 (Reuters) - VELOXIS PHARMACEUTICALS A/S ::SAID ON TUESDAY Q1 REVENUE $4.0 MLN VS $1.5 MLN YR AGO.Q1 OPERATING LOSS $5.2 MLN VS LOSS $6.9 MLN YR AGO .Q1 NET LOSS $5.9 MLN VS LOSS $7.1 MLN YR AGO.VELOXIS MAINTAINS ITS 2017 OUTLOOK OF OPERATING LOSS BEFORE THE RECOGNITION OF INCOME FROM LICENSE AGREEMENTS AND BEFORE ACCOUNTING FOR STOCK COMPENSATION TO BE IN THE RANGE OF USD 5 – 15 MILLION..  Full Article

Veloxis increases share capital in connection with exercise of warrants
Tuesday, 4 Apr 2017 01:00am EDT 

VELOXIS PHARMACEUTICALS A/S : CAPITAL INCREASED BY 1,000,000 NEW SHARES WITH A NOMINAL VALUE OF DKK 0.10 EACH CORRESPONDING TO NOMINALLY DKK 100,000 AS A CONSEQUENCE OF EXERCISE OF WARRANTS .AS A RESULT OF EMPLOYEE'S INVESTMENT IN COMPANY PROCEEDS TO VELOXIS PHARMACEUTICALS A/S FROM CAPITAL INCREASE AMOUNTS TO DKK 350,000.  Full Article

Veloxis Pharmaceuticals announces New Jersey office closure
Tuesday, 28 Feb 2017 09:30am EST 

Veloxis Pharmaceuticals A/S : US subsidiary, Veloxis Pharmaceuticals Inc., has decided to close its office in Edison, New Jersey effective February 28, 2017 .All of the company’s operations will now be based out of its Cary, North Carolina office.  Full Article

Veloxis Pharmaceuticals announces amended and restated loan and security agreement
Wednesday, 8 Feb 2017 05:07am EST 

Veloxis Pharmaceuticals A/S : Agreed to amend and restate terms of its previously announced loan and security agreement with Lundbeckfond Invest A/S and Novo A/S. .Terms of amended and restated agreement make available an additional $10 million in financing at an interest rate of 12 pct, payable annually in arrears.  Full Article

Veloxis Q3 net loss narrows to $7.6 million
Wednesday, 16 Nov 2016 09:00am EST 

Veloxis Pharmaceuticals A/S : Q3 net revenue $2.2 million versus $1.8 million in Q2 and $0.5 million year ago . Q3 net loss $7.6 million versus loss $9.3 million in Q2 and loss $7.2 million year ago .Maintains its 2016 outlook of operating loss and net loss of $25.0 - 31.0 million.  Full Article

Veloxis Pharmaceuticals Q2 operating loss widens to $9.6 million
Thursday, 25 Aug 2016 01:33am EDT 

Veloxis Pharmaceuticals A/S : Said on Wednesdays Q2 revenue $1.8 million versus $783,000 year ago . Q2 operating loss $9.6 million versus loss $5.3 million year ago . Q2 pre-tax loss $9.3 million versus loss $6.0 million year ago .Has revised 2016 outlook to operating loss and net loss of $25.0 million – $31.0 million (previously reported $17.6 million – $23.4 million).  Full Article

Veloxis Pharmaceuticals Q2 operating loss widens to $9.6 million
Wednesday, 24 Aug 2016 12:31pm EDT 

Veloxis Pharmaceuticals A/S : Said on Wednesdays Q2 revenue $1.8 million versus $783,000 year ago . Q2 operating loss $9.6 million versus loss $5.3 million year ago . Q2 pre-tax loss $9.3 million versus loss $6.0 million year ago .Has revised 2016 outlook to operating loss and net loss of $25.0 million – $31.0 million (previously reported $17.6 million – $23.4 million).  Full Article

Veloxis Pharmaceuticals raises DKK 4.1 mln from exercise of warrants
Monday, 13 Jun 2016 02:00am EDT 

Veloxis Pharmaceuticals A/S : Capital increase from exercise of warrants amounts to 4.1 million Danish crowns ($620,977) .About 11.7 million new shares were subscribed for at 0.35 crown per share (6.9 million shares) and 0.36 crown per share (4.8 million shares).  Full Article

Veloxis Pharmaceuticals Q1 operating loss at $6.9 mln
Thursday, 19 May 2016 03:35am EDT 

Veloxis Pharmaceuticals A/S : Said on Wednesday Q1 revenue $1.5 million versus $647,000 year ago . Q1 operating loss $6.9 million versus loss $7.0 million year ago . Q1 pre-tax loss $7.1 million versus loss $4.3 million year ago .Maintains its 2016 outlook of an operating and net loss of 120 million – 160 million Danish crowns ($17.6–23.4 million based on an assumed average exchange rate of 1 $= 6.83 Danish crown).  Full Article

Veloxis Pharmaceuticals appoints Michael Thomas Heffernan new chairman
Wednesday, 6 Apr 2016 09:05am EDT 

Veloxis Pharmaceuticals A/S:Board of directors constituted itself with Michael Thomas Heffernan as chairman of board.  Full Article

More From Around the Web

BRIEF-Veloxis Pharmaceuticals Q1 operating loss narrows to $5.2 mln

* VELOXIS MAINTAINS ITS 2017 OUTLOOK OF OPERATING LOSS BEFORE THE RECOGNITION OF INCOME FROM LICENSE AGREEMENTS AND BEFORE ACCOUNTING FOR STOCK COMPENSATION TO BE IN THE RANGE OF USD 5 – 15 MILLION.